173 related articles for article (PubMed ID: 35822553)
21. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group.
van Hoogstraten HJ; Vleggaar FP; Boland GJ; van Steenbergen W; Griffioen P; Hop WC; van Hattum J; van Berge Henegouwen GP; Schalm SW; van Buuren HR
Am J Gastroenterol; 2000 Aug; 95(8):2015-22. PubMed ID: 10950051
[TBL] [Abstract][Full Text] [Related]
22. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses.
van Hoogstraten HJ; Wolfhagen FH; van de Meeberg PC; Kuiper H; Nix GA; Becx MC; Hoek AC; van Houte DP; Rijk MC; Salemans JM; Scherpenisse J; Schrijver M; Smit AM; Spoelstra P; Stadhouders PH; Tan TG; Hop WC; ten Kate FJ; vanBerge-Henegouwen GP; Schalm SW; van Buuren HR
J Hepatol; 1998 Sep; 29(3):417-23. PubMed ID: 9764988
[TBL] [Abstract][Full Text] [Related]
23. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
Hegade VS; Khanna A; Walker LJ; Wong LL; Dyson JK; Jones DEJ
Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
[TBL] [Abstract][Full Text] [Related]
24. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial.
Färkkilä M; Karvonen AL; Nurmi H; Nuutinen H; Taavitsainen M; Pikkarainen P; Kärkkäinen P
Hepatology; 2004 Dec; 40(6):1379-86. PubMed ID: 15565569
[TBL] [Abstract][Full Text] [Related]
25. Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value.
de Vries EM; Wang J; Leeflang MM; Boonstra K; Weersma RK; Beuers UH; Geskus RB; Ponsioen CY
Liver Int; 2016 Dec; 36(12):1867-1875. PubMed ID: 26945698
[TBL] [Abstract][Full Text] [Related]
26. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period.
Stiehl A; Walker S; Stiehl L; Rudolph G; Hofmann WJ; Theilmann L
J Hepatol; 1994 Jan; 20(1):57-64. PubMed ID: 8201224
[TBL] [Abstract][Full Text] [Related]
27. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.
Olsson R; Boberg KM; de Muckadell OS; Lindgren S; Hultcrantz R; Folvik G; Bell H; Gangsøy-Kristiansen M; Matre J; Rydning A; Wikman O; Danielsson A; Sandberg-Gertzén H; Ung KA; Eriksson A; Lööf L; Prytz H; Marschall HU; Broomé U
Gastroenterology; 2005 Nov; 129(5):1464-72. PubMed ID: 16285948
[TBL] [Abstract][Full Text] [Related]
28. Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF.
Fossdal G; Mjelle AB; Wiencke K; Bjørk I; Gilja OH; Folseraas T; Karlsen TH; Rosenberg W; Giil LM; Vesterhus M
JHEP Rep; 2021 Oct; 3(5):100328. PubMed ID: 34485881
[TBL] [Abstract][Full Text] [Related]
29. A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: a Pilot Study.
Rahimpour S; Nasiri-Toosi M; Khalili H; Ebrahimi-Daryani N; Nouri-Taromlou MK; Azizi Z
J Gastrointestin Liver Dis; 2016 Dec; 25(4):457-464. PubMed ID: 27981301
[TBL] [Abstract][Full Text] [Related]
30. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial.
de Vries E; Bolier R; Goet J; Parés A; Verbeek J; de Vree M; Drenth J; van Erpecum K; van Nieuwkerk K; van der Heide F; Mostafavi N; Helder J; Ponsioen C; Oude Elferink R; van Buuren H; Beuers U;
Gastroenterology; 2021 Feb; 160(3):734-743.e6. PubMed ID: 33031833
[TBL] [Abstract][Full Text] [Related]
31. [Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis].
Ahn DW
Korean J Gastroenterol; 2020 May; 75(5):246-256. PubMed ID: 32448856
[TBL] [Abstract][Full Text] [Related]
32. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis.
Harnois DM; Angulo P; Jorgensen RA; Larusso NF; Lindor KD
Am J Gastroenterol; 2001 May; 96(5):1558-62. PubMed ID: 11374699
[TBL] [Abstract][Full Text] [Related]
33. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
Mitchell SA; Bansi DS; Hunt N; Von Bergmann K; Fleming KA; Chapman RW
Gastroenterology; 2001 Oct; 121(4):900-7. PubMed ID: 11606503
[TBL] [Abstract][Full Text] [Related]
34. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.
Imam MH; Sinakos E; Gossard AA; Kowdley KV; Luketic VA; Edwyn Harrison M; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Keach J; DeCook AC; Enders F; Lindor KD
Aliment Pharmacol Ther; 2011 Nov; 34(10):1185-92. PubMed ID: 21957881
[TBL] [Abstract][Full Text] [Related]
35. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis.
Stanich PP; Björnsson E; Gossard AA; Enders F; Jorgensen R; Lindor KD
Dig Liver Dis; 2011 Apr; 43(4):309-13. PubMed ID: 21251891
[TBL] [Abstract][Full Text] [Related]
36. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
[TBL] [Abstract][Full Text] [Related]
37. Ursodeoxycholic acid for primary sclerosing cholangitis.
Chazouillères O; Poupon R; Capron JP; Metman EH; Dhumeaux D; Amouretti M; Couzigou P; Labayle D; Trinchet JC
J Hepatol; 1990 Jul; 11(1):120-3. PubMed ID: 1975818
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.
Duan W; Ou X; Wang X; Wang Y; Zhao X; Wang Q; Wu X; Zhang W; Ma H; You H; Jia J
Rev Esp Enferm Dig; 2018 Sep; 110(9):557-563. PubMed ID: 29739227
[TBL] [Abstract][Full Text] [Related]
39. Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study.
Reig A; Álvarez-Navascués C; Vergara M; Gómez-Domínguez E; Gallego-Moya A; Pérez-Medrano IM; Fábrega E; Hernández-Guerra M; Berenguer M; Estevez P; Arencibia A; Morillas RM; Horta D; Albillos A; Casado M; De la Cruz G; Fernandez-Bonilla E; Molina E; Hijona L; Diago M; Fernández-Rodriguez CM; González-Santiago JM; Sala M; Gómez-Camarero J; Romero-Gomez M; Suárez F; Vargas V; Ferre-Aracil C; Andrade RJ; Chahri N; Parés A
Am J Gastroenterol; 2021 Nov; 116(11):2250-2257. PubMed ID: 34158466
[TBL] [Abstract][Full Text] [Related]
40. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.
Cheung AC; Lapointe-Shaw L; Kowgier M; Meza-Cardona J; Hirschfield GM; Janssen HL; Feld JJ
Aliment Pharmacol Ther; 2016 Jan; 43(2):283-93. PubMed ID: 26559762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
